Updated: February 12, 2026 | Read time 1 min
Turning heads with Nasal Microsampling
Diag-Nose.io’s nasal liquid biopsy device, the ABEL Microsampler®, has just been recognised with a prestigious Australian Good Design Award (GDA) Winner accolade in the Product Design category.
Designed by engineers Jonathan Limpah (Senior Engineer) and Brian Occhipinti at Diag-Nose.io, the ABEL Microsampler® demonstrates exactly how thoughtful design can transform complex science into human-centric solutions.
The 2025 GDA awards theme ‘Rewarding, Defining and Celebrating Better _______’ promotes initiatives that translate research and ideas into tangible benefits for patients and clinicians.
Our dedicated engineering team rose to the challenge with ABEL. The device promotes better nasal fluid sampling; better site-specificity and better volume precision. The award recognises this, and moves us even closer to realising our goals.
Achieve better research, better diagnosis, and better patient-treatment matching.
The award underscores the transformative potential of combining engineering excellence with medical research, paving the way for more accurate diagnostics, faster discoveries, and improved patient outcomes.
In response to the exciting news, Limpah reiterated the importance of the device for the future of medical research.
“We designed the ABEL Microsampler® to simplify precision nasal sampling. It requires no specialised training or complex equipment, just reliable data to better understand and treat respiratory disease. We’re honoured to have our work recognised with a Good Design Award, and it’s inspiring to see design-led innovation making a real impact in healthcare.”
Why does this award matter for our company?
With the ABEL Microsampler® receiving national recognition, the team at Diag-Nose.io are extremely proud to see its commitment to innovation, precision, and human-centered design validated.
Ultimately, the award is further evidence of the potential of the device as an industry lead in precision medicine.
The device is already being recognised by lead researchers including Dr Jennifer Mulligan at the University of Florida. Mulligan is now using the ABEL Microsampler to progress her work in uncovering the “culprits” driving inflammatory conditions.
In her own words,
"The ABEL Microsampler will be a game-changer for our research.”
“We are excited about its ability to collect precise and high-quality nasal fluid samples with minimal discomfort, enabling us to generate robust data and delve deeper into biomarker discovery for respiratory diseases. This tool bridges critical gaps in sampling methodologies and will help us set a new standard for nasal fluid research."
As adoption grows across research and clinical settings, the ABEL Microsampler® is poised to redefine nasal sampling standards, supporting a future where better data leads directly to better health.